409 related articles for article (PubMed ID: 24525502)
1. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
Fleischmann A; Thalmann GN; Perren A; Seiler R
Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
[TBL] [Abstract][Full Text] [Related]
2. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder.
Kiss B; Skuginna V; Fleischmann A; Bell RH; Collins C; Thalmann GN; Seiler R
Urol Oncol; 2015 Apr; 33(4):166.e1-8. PubMed ID: 25596645
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Voskuilen CS; Oo HZ; Genitsch V; Smit LA; Vidal A; Meneses M; Necchi A; Colecchia M; Xylinas E; Fontugne J; Sibony M; Rouprêt M; Lenfant L; Côté JF; Buser L; Saba K; Furrer MA; van der Heijden MS; Daugaard M; Black PC; van Rhijn BWG; Hendricksen K; Poyet C; Seiler R
Am J Surg Pathol; 2019 Dec; 43(12):1600-1610. PubMed ID: 31524642
[TBL] [Abstract][Full Text] [Related]
5. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M
Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
9. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Value of Tumor Regression Grades Combined With TNM Classification in Patients With Muscle-Invasive Bladder Cancer Who Underwent Neoadjuvant Chemotherapy Followed by Radical Cystectomy.
Gronostaj K; Czech AK; Fronczek J; Drobniak A; Okon K; Chlosta PL; Szczeklik W
Clin Genitourin Cancer; 2019 Dec; 17(6):e1203-e1211. PubMed ID: 31588010
[TBL] [Abstract][Full Text] [Related]
11. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.
Vecchio FM; Valentini V; Minsky BD; Padula GD; Venkatraman ES; Balducci M; Miccichè F; Ricci R; Morganti AG; Gambacorta MA; Maurizi F; Coco C
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):752-60. PubMed ID: 15936556
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2008 Jul; 54(1):126-32. PubMed ID: 18248875
[TBL] [Abstract][Full Text] [Related]
14. [The prognostic value of adjuvant and neoadjuvant chemotherapy in total cystectomy for locally advanced bladder cancer].
Habuchi T; Kakehi Y; Terachi T; Ogawa O; Yoshida O
Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):809-17. PubMed ID: 10565159
[TBL] [Abstract][Full Text] [Related]
15. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
17. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
